'On standalone basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of RPG Life Sciences has increased 12.68% to Rs 143.09 crore. Operating profit margin has jumped from 16.32% to 17.81%, leading to 23.02% rise in operating profit to Rs 25.49 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.81% to 18.87%. Purchase of finished goods cost rose from 11.61% to 14.89%. Employee cost decreased from 24.96% to 22.18%. Other expenses rose from 25.49% to 26.17%.
Other income up 206.67% to Rs 5.06 crore. PBIDT rose 36.57% to Rs 30.55 crore. Provision for interest up 28.57% to Rs 0.18 crore. Loan funds remained nil. Inventories declined from Rs 101.00 crore as of 31 March 2024 to Rs 92.98 crore as of 31 March 2025. Sundry debtors were hi...
Pleaselogin & subscribe to view the full report.
More Reports
|
|